

## Galien MedStartup Award: Eukarÿs nominated among the three finalists



**PRIX GALIEN**  
MEDSTARTUP

Evry, Friday October 18, 2019,

Eukarÿs announces today its nomination to the Prix Galien - MedStartup in the category best collaboration with the pharmaceutical or biotechnology industry. This competition, co-organized by Business France and the prestigious Galien Foundation, brings together innovators and key accounts to accelerate access to innovation and encourages the adoption of new technologies in the human health field. Eukarÿs was nominated for its partnership with the Molecular Virology and Oncology Laboratory led by Dr. Maya Shmulevitz at the University of Alberta. This work culminated in the development of the C3P3 system for the bioproduction of oncolytic reoviruses. The awards ceremony will take place on October 23 and 24 in New York at the Alexandria Life Sciences Center.

### **About Eukarÿs:**

Eukarÿs is a French biotech company of the Genopole Biocluster that is developing the first system and to date the only eukaryotic artificial expression called C3P3. This system allows the high-throughput production of mature target messenger RNAs and thus proteins of interest in the host cell. Through this system, Eukarÿs is developing a radically innovative approach to synthetic gene therapy that provides solutions to the challenges faced by existing gene therapy approaches. Eukarÿs also uses the C3P3 system to develop high performance bioproduction systems for biologic drugs, including proteins, recombinant viruses and VLP vaccines.

**Contact** : Eukarÿs SAS | Genopole Campus 3 | 4 rue Pierre Fontaine | 91058 Evry Cedex, France | [contact@eukarys.com](mailto:contact@eukarys.com) | [www.eukarys.com](http://www.eukarys.com)